Crohn's Disease and Colitis Trial, Recruiting NCT03809728 Sponsor: Central Hospital, Nancy, France Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT03809728
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older
  • People who have a confirmed diagnosis of Crohn's disease (CD) or ulcerative colitis (UC), based on clinical, laboratory, imaging, endoscopy, or tissue analysis results
  • People who weigh 45 kg (approximately 99 pounds) or more
  • People who are registered members of the French Social Security system

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose colitis has not been clearly identified as a specific type
  • People who do not have a confirmed diagnosis of Crohn's disease
  • Women who could become pregnant and are not using a method of contraception
  • People who are pregnant or currently breastfeeding
  • People covered by certain specific articles of the French Public Health Code, which relate to protected groups such as people under legal guardianship or those unable to give consent (confirm with trial site)
  • People who do not have the mental or legal capacity to give their own consent to participate
  • People under 18 years of age who are under the authority of a judicial or administrative decision (confirm with trial site)
  • People under any form of legal protection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Adeline GERMAIN, MD, PhD, CHRU Nancy

Phone: +33383153120

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 December 2019
Est. completion
10 December 2034

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Proportion of patients who have lost response to biotherapies (anti-TNF, ustekinumab, vedolizumab).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov